IL223783D0 - Pro-neurogenic compounds - Google Patents

Pro-neurogenic compounds

Info

Publication number
IL223783D0
IL223783D0 IL223783A IL22378312A IL223783D0 IL 223783 D0 IL223783 D0 IL 223783D0 IL 223783 A IL223783 A IL 223783A IL 22378312 A IL22378312 A IL 22378312A IL 223783 D0 IL223783 D0 IL 223783D0
Authority
IL
Israel
Prior art keywords
pro
neurogenic compounds
neurogenic
compounds
Prior art date
Application number
IL223783A
Other versions
IL223783A (en
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/832,056 priority Critical patent/US8362277B2/en
Priority to US13/177,981 priority patent/US9095572B2/en
Priority to PCT/US2011/043185 priority patent/WO2012006419A2/en
Application filed by Univ Texas filed Critical Univ Texas
Publication of IL223783D0 publication Critical patent/IL223783D0/en
Publication of IL223783A publication Critical patent/IL223783A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
IL223783A 2009-01-09 2012-12-20 Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament IL223783A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/832,056 US8362277B2 (en) 2009-01-09 2010-07-07 Pro-neurogenic compounds
US13/177,981 US9095572B2 (en) 2009-01-09 2011-07-07 Pro-neurogenic compounds
PCT/US2011/043185 WO2012006419A2 (en) 2010-07-07 2011-07-07 Pro-neurogenic compounds

Publications (2)

Publication Number Publication Date
IL223783D0 true IL223783D0 (en) 2013-03-05
IL223783A IL223783A (en) 2018-06-28

Family

ID=45441795

Family Applications (1)

Application Number Title Priority Date Filing Date
IL223783A IL223783A (en) 2009-01-09 2012-12-20 Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament

Country Status (10)

Country Link
US (4) US9095572B2 (en)
EP (1) EP2590647B1 (en)
JP (1) JP6126528B2 (en)
CN (1) CN103415289B (en)
AU (1) AU2011274787B2 (en)
BR (1) BR112013000414A2 (en)
CA (1) CA2804161A1 (en)
DK (1) DK2590647T3 (en)
IL (1) IL223783A (en)
WO (1) WO2012006419A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6075660B2 (en) * 1987-03-23 2017-02-08 ケーシーアイ ライセンシング インコーポレイテッド Ceramic foam filter
RU2007139634A (en) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) New thiazole-, triazole- or oxadiazole-containing tetracyclic compounds
RU2544856C2 (en) 2008-01-25 2015-03-20 Сергей Олегович Бачурин NEW 2,3,4,5-TETRAHYDRO-1-PYRIDO[4,3-b]INDOLE DERIVATIVES AND METHODS FOR USING THEM
US8338447B2 (en) 2008-03-24 2012-12-25 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
TWI450900B (en) 2008-03-24 2014-09-01 Medivation Technologies Inc Bridged heterocyclic compounds and methods of use
JP5551708B2 (en) 2008-10-31 2014-07-16 メディベイション テクノロジーズ， インコーポレイテッド Azepino [4,5-b] indole compounds and methods of use thereof
EP2590647B1 (en) 2010-07-07 2017-11-08 Board of Regents of the University of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
WO2014031125A1 (en) 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
JP5766614B2 (en) 2009-01-09 2015-08-19 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ Neurogenesis-promoting compound
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
EP2424364A4 (en) 2009-04-29 2012-12-19 Medivation Technologies Inc Pyrido [4,3-b] indoles and methods of use
US9079904B2 (en) 2009-09-23 2015-07-14 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
EP2480078A4 (en) 2009-09-23 2013-03-06 Medivation Technologies Inc Pyrido[4,3-b]indoles and methods of use
BR112012006648A2 (en) 2009-09-23 2019-09-24 Medivation Neurology Inc compound, method of treating a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder or a neuronal disorder, pharmaceutical composition and kit
WO2011103433A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
EP2675459A4 (en) 2011-02-18 2014-08-06 Medivation Technologies Inc Compounds and methods of treating diabetes
US9035056B2 (en) 2011-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
US9199985B2 (en) 2011-02-18 2015-12-01 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
AU2012338362B2 (en) * 2011-11-15 2017-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Tricyclic compounds, compositions comprising them and uses thereof
JP2013193980A (en) * 2012-03-19 2013-09-30 Toray Fine Chemicals Co Ltd Low viscosity epoxy compound, and method for producing the same
US9265772B2 (en) 2012-05-11 2016-02-23 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
KR20150032333A (en) 2012-07-17 2015-03-25 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Indolecarbonitriles as selective androgen receptor modulators
WO2014016267A1 (en) 2012-07-26 2014-01-30 F. Hoffmann-La Roche Ag Benzisoxazole modulators of neurogenesis
JP5974177B2 (en) 2012-08-06 2016-08-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Piperazino [1,2-a] indol-1-ones and [1,4] diazepino [1,2-a] indol-1-ones
WO2014031986A1 (en) 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
MX2015002398A (en) * 2012-10-01 2015-06-05 Hoffmann La Roche Benzimidazol.es as cns active agents.
AR093519A1 (en) 2012-11-20 2015-06-10 F Hoffmann-La Roche Ag 1,6-naphthyridines
WO2014079850A1 (en) 2012-11-23 2014-05-30 F. Hoffmann-La Roche Ag Substituted heterocyclic derivatives
MX2015013915A (en) 2013-04-02 2015-12-11 Hoffmann La Roche Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-on e.
JP6113354B2 (en) 2013-05-03 2017-04-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Neurogenesis stimulating isoquinoline derivative
JP6231691B2 (en) * 2013-09-12 2017-11-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Indole-carboxamide derivatives
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
WO2015070234A2 (en) * 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
EP3068781B1 (en) 2013-11-12 2017-12-20 F.Hoffmann-La Roche Ag Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders
CA2935270A1 (en) 2014-01-20 2015-07-23 F. Hoffmann-La Roche Ag N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders
TW201605835A (en) 2014-04-07 2016-02-16 Reset Therapeutics Inc As Cryptochromes modifier comprising the carbazole of Amides, ureas and carbamic acid esters
CN105884767B (en) * 2015-11-24 2018-01-19 西华大学 Pyrido [3,4 b] indole derivatives of 9 substitutions and preparation method thereof and the purposes as SIRT protein inhibitors

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE539438A (en) 1954-07-01
US3518250A (en) 1965-12-17 1970-06-30 Ibm Substitution of imino-heterocyclic compounds
US3409628A (en) 1966-05-12 1968-11-05 Hoffmann La Roche 5-(3-pyridylethyl)pyridoindole derivatives
US4495281A (en) 1982-10-21 1985-01-22 Miles Laboratories, Inc. Tricyclic antidepressant drug immunogens, antibodies, labeled conjugates, and related derivatives
JPH04217657A (en) * 1990-10-19 1992-08-07 Toyo Gosei Kogyo Kk 4-(n-arylcarbamoylalkylthio)phenolic compound and heat-sensitive recording material produced by using the same
JP2684252B2 (en) 1991-03-08 1997-12-03 富士写真フイルム株式会社 The silver halide color photographic light-sensitive material
WO1992021660A1 (en) 1991-05-29 1992-12-10 Pfizer, Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5234923A (en) 1991-12-16 1993-08-10 E. R. Squibb & Sons, Inc. Substitute indole and benzimidazole derivatives
EP0823905A1 (en) 1995-05-05 1998-02-18 Novo Nordisk A/S Novel heterocyclic chemistry
RU2106864C1 (en) 1995-10-23 1998-03-20 Николай Серафимович Зефиров New approach to treatment of alzheimer's disease
AU741839B2 (en) 1996-10-04 2001-12-13 Novo Nordisk A/S N-substituted azaheterocyclic compounds
US6468996B1 (en) 1998-10-21 2002-10-22 Novo Nordisk A/S Substituted hetero-polycyclic compounds as PPARα and PPARγ activators
AU6190299A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
AU6047300A (en) 1999-06-21 2001-01-09 Eli Lilly And Company Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistanceassociated protein-1 (mrp-1)
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
EP1094063A1 (en) * 1999-10-18 2001-04-25 Applied Research Systems ARS Holding N.V. 9-(Piperazinylalkyl)carbazoles as Bax-modulators
GB9925880D0 (en) 1999-11-01 1999-12-29 British Tech Group Int B-Carboline derivatives
AT376996T (en) 2000-01-13 2007-11-15 Amgen Inc Antibacterial agents
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
US6340548B1 (en) 2000-03-16 2002-01-22 Imation Corp. Organophotoreceptors for electrophotography featuring novel charge transport compounds
DK1268418T3 (en) 2000-03-27 2006-09-25 Applied Research Systems Pharmaceutically active pyrrolidine derivatives as Bax inhibitors
AU2002236438A1 (en) 2000-11-08 2002-05-21 Massachusetts Institute Of Technology Compositions and methods for treatment of mild cognitive impairment
WO2002060867A2 (en) 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
AU2002362641A1 (en) 2001-07-13 2003-04-22 The University Of Chicago Crosslinkable monomers for novel nonlinear optical polymers
CA2453537A1 (en) 2001-08-08 2003-02-20 Pharmacia & Upjohn Company Therapeutic 1h-pyrido¬4,3-b|indoles
US6835513B2 (en) 2002-03-28 2004-12-28 Samsung Electronic Co., Ltd. Carbazole based charge transport compounds
US6864025B2 (en) 2002-03-28 2005-03-08 Samsung Electronics Co., Ltd. Sulfonyldiphenylene-based charge transport compositions
JP2005537228A (en) 2002-04-25 2005-12-08 ファルマシア・コーポレーション Piperidinyl - and piperazinyl - their use as sulfonyl methyl hydroxamic acid and protease inhibitors
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
AT466856T (en) 2002-12-10 2010-05-15 Virochem Pharma Inc Compounds and methods for treating or preventing flavirus infections
CN100503607C (en) 2003-06-02 2009-06-24 新疆华世丹药物研究有限责任公司 Yageine derivative compounds and their uses
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
CN1886133B (en) 2003-12-04 2010-12-01 财团法人卫生研究院 Indole compounds
RU2283108C2 (en) 2003-12-08 2006-09-10 Сергей Олегович Бачурин GEROPROTECTING AGENT BASED ON HYDROGENATED PYRIDO[4,3-b]INDOLES (VARIANTS), PHARMACOLOGICAL AGENT BASED ON THEREOF AND METHOD FOR ITS USING
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
DE602004011400T2 (en) * 2004-01-29 2009-01-22 Cellzome Ag Treatment of neurodeegenerative diseases with gpr49
WO2005085227A1 (en) 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
US20050244674A1 (en) 2004-04-28 2005-11-03 Jsr Corporation Phosphorescent polymer and production process thereof, organic electroluminescence device, and metal conplex-containing compond and production process thereof
US7445877B2 (en) 2004-06-10 2008-11-04 Samsung Electronics Co., Ltd. Charge transport materials having a central disulfane linkage
CN1738069A (en) 2004-08-17 2006-02-22 国际商业机器公司 Method for manufacturing electronic device having an electrode with enhanced injection properties and said electronic device
WO2006041624A2 (en) 2004-09-20 2006-04-20 Washington University Nad biosynthesis systems
WO2006044707A1 (en) 2004-10-13 2006-04-27 Smithkline Beecham Corporation Chemical compounds
WO2006044425A2 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2006077954A1 (en) * 2005-01-21 2006-07-27 Kyowa Hakko Kogyo Co., Ltd. Remedy for neurological disease
AU2006218403A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
CA2605166A1 (en) 2005-04-15 2006-10-26 Tgen Methods, heterocyclic compounds and compositions with genotype selective anitcancer activity
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007041697A2 (en) 2005-10-04 2007-04-12 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
US7438916B2 (en) 2005-10-14 2008-10-21 Virginia Tech Intellectual Properties, Inc. Therapeutic target for protozoal diseases
AU2007249399A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP3369738A1 (en) 2005-11-18 2018-09-05 Cornell Research Foundation, Inc. Nicotinyl riboside compositions and methods of use
CN101360422B (en) 2005-11-23 2013-10-23 得克萨斯大学体系董事会 Oncogenic Ras-specific cytotoxic compound and methods of usethereof
DE102005062741A1 (en) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorenes and carbazoles as ligands of the ep2 receptor
WO2007079239A2 (en) 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
KR100814109B1 (en) 2006-01-09 2008-03-14 한국생명공학연구원 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
RU2338537C2 (en) 2006-01-25 2008-11-20 Сергей Олегович Бачурин AGENT FOR TREATMENT OF SCHIZOPHRENIA ON BASIS OF HYDROGENATED PYDIDO (4,3-b) INDOLES (VERSIONS), PHARMACOLOGICAL AGENT ON ITS BASIS AND METHOD OF ITS APPLICATION
BRPI0707557A2 (en) * 2006-02-07 2011-05-10 Mtsubishi Tanabe Pharma Corporantion neurogenesis measured by 4-acylaminopyridine derivative
JP2007223916A (en) 2006-02-21 2007-09-06 Institute Of Physical & Chemical Research Antibacterial agent
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
CA2652416A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Treatment for depressive disorders
WO2008021745A2 (en) 2006-08-16 2008-02-21 Itherx Pharmaceuticals, Inc. Hepatitis c virus entry inhibitors
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
RU2329044C1 (en) 2006-11-16 2008-07-20 Андрей Александрович Иващенко Ligands of 5-ht6 receptors, pharmaceutical formulation, production method and medical product
RU2338745C1 (en) 2007-03-21 2008-11-20 Андрей Александрович Иващенко SUBSTITUTED 2,3,4,5-TETRAHYDRO-1N-PYRIDO[4,3-b]INDOLES, METHOD OF OBTAINING THEM AND USE
RU2339637C1 (en) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Histamine receptor blockers for pharmaceutical compositions of antiallergic and autoimmune effect
RU2334747C1 (en) 2007-04-05 2008-09-27 Андрей Александрович Иващенко SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-b]INDOLES, METHOD OF PRODUCTION AND APPLICATION THEREOF
JP5540701B2 (en) 2007-06-21 2014-07-02 コニカミノルタ株式会社 Organic electroluminescence element material
MX2010003230A (en) 2007-09-25 2010-04-07 Topotarget Uk Ltd Methods of synthesis of certain hydroxamic acid compounds.
CN101139347B (en) 2007-10-15 2010-11-24 新疆华世丹药物研究有限责任公司 Banisterine derivative compound and uses thereof
RU2007139634A (en) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) New thiazole-, triazole- or oxadiazole-containing tetracyclic compounds
CN101429198B (en) 2007-11-09 2013-10-23 新疆华世丹药物研究有限责任公司 Banisterine derivant and uses thereof
EP2236511A4 (en) 2007-12-21 2011-04-13 Alla Chem Llc Ligands of alpha-adrenoceptors and of dopamine, histamine, imidazoline and serotonin receptors and the use thereof
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester Method for altering the lifespan of eukaryotic organisms
RU2544856C2 (en) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин NEW 2,3,4,5-TETRAHYDRO-1-PYRIDO[4,3-b]INDOLE DERIVATIVES AND METHODS FOR USING THEM
US9079999B2 (en) 2008-02-26 2015-07-14 Rigoberto Advincula Methods for preparing polymer coatings by electrochemical grafting of polymer brushes, compositions prepared thereby and compositions for preparing the coatings
US8338447B2 (en) * 2008-03-24 2012-12-25 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
US7989127B2 (en) 2008-04-30 2011-08-02 Xerox Corporation Carbazole containing charge transport layer photoconductors
KR20100008720A (en) * 2008-07-16 2010-01-26 호 진 안 Call bell system
EP2340040B1 (en) 2008-10-22 2019-01-16 F.Hoffmann-La Roche Ag Modulation of axon degeneration
AR073923A1 (en) 2008-10-31 2010-12-09 Medivation Technologies Inc Pyrido (4,3-b) indoles containing rigid radicals
JP5551708B2 (en) * 2008-10-31 2014-07-16 メディベイション テクノロジーズ， インコーポレイテッド Azepino [4,5-b] indole compounds and methods of use thereof
JP5766614B2 (en) 2009-01-09 2015-08-19 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ Neurogenesis-promoting compound
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
EP2590647B1 (en) 2010-07-07 2017-11-08 Board of Regents of the University of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
WO2014031125A1 (en) 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2011019417A1 (en) * 2009-04-29 2011-02-17 Medivation Technologies, Inc. Pyrido [4, 3-b] indoles and methods of use
RU2009128817A (en) * 2009-07-28 2011-02-10 Общество с ограниченной ответственностью "Инномед" (RU) Hydrogen pyrido [4,3-b] indoles derivatives, pharmaceutical composition, methods for producing and use
US8763653B2 (en) 2009-08-06 2014-07-01 Harro Höfliger Verpackungsmaschinen GmbH Filling assembly for metering powder and method for operating such a filling assembly
AU2010298167B2 (en) 2009-09-23 2015-12-24 Medivation Technologies, Inc. Pyrido(3,4-b)indoles and methods of use
WO2011117668A1 (en) 2010-03-22 2011-09-29 Council Of Scientific & Industrial Research Carbazole linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof
US20120122924A1 (en) 2010-11-15 2012-05-17 Abbott Laboratories Nampt inhibitors
CN103998027A (en) 2011-10-15 2014-08-20 霍夫曼-拉罗奇有限公司 Methods of using SCD1 antagonists for cancer therapy
WO2014031986A1 (en) 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2015035051A1 (en) 2013-09-04 2015-03-12 Board Of Regents Of The University Of Texas System Methods and compositions for selective and targeted cancer therapy
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof

Also Published As

Publication number Publication date
BR112013000414A2 (en) 2016-05-17
US20180127367A1 (en) 2018-05-10
US20160362373A1 (en) 2016-12-15
CN103415289A (en) 2013-11-27
AU2011274787B2 (en) 2016-06-16
WO2012006419A2 (en) 2012-01-12
IL223783A (en) 2018-06-28
WO2012006419A3 (en) 2013-08-01
DK2590647T3 (en) 2018-02-12
CN103415289B (en) 2017-04-12
US9446022B2 (en) 2016-09-20
EP2590647B1 (en) 2017-11-08
JP2013541495A (en) 2013-11-14
US9095572B2 (en) 2015-08-04
EP2590647A4 (en) 2014-05-21
US20160074361A1 (en) 2016-03-17
AU2011274787A1 (en) 2013-01-10
JP6126528B2 (en) 2017-05-10
EP2590647A2 (en) 2013-05-15
CA2804161A1 (en) 2012-01-12
US9884820B2 (en) 2018-02-06
US20120022096A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
AP3107A (en) 5-Alkynyl-pyrimidines
EP2566479A4 (en) Azaindazoles
GB201215746D0 (en) Rotocraft
EP2547244A4 (en) Combination juicer-blender
GB201007286D0 (en) New compounds
HRP20170903T1 (en) Substituted pyrrolidine-2-carboxamides
IL223783D0 (en) Pro-neurogenic compounds
GB201020179D0 (en) New compounds
GB201005589D0 (en) Novel compounds
GB201008134D0 (en) Compounds
HRP20181800T1 (en) Well
GB201015949D0 (en) Compounds
AP3607A (en) Substituted imidazopyridazines
EP2640189A4 (en) 3-deutero-pomalidomide
EP2622917A4 (en) Positioning
IL221901A (en) Morpholinylquinazolines
GB201007203D0 (en) Novel compounds
HK1181747A1 (en) 1-hydroxyimino-3-phenyl-propanes 1--3--
PL2619208T3 (en) Imidazotriazinone compounds
HK1179966A1 (en) Tetrahydro-pyrido-pyrimidine derivatives --
SI2616465T1 (en) Triazine-oxadiazoles
GB201112400D0 (en) No details
GB201205984D0 (en) No details
SI2569319T1 (en) Heteroaryl-cyclohexyl-tetraazabenzošećazulenes
EP2622916A4 (en) Positioning

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed